If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Bluescape Opportunities Acquisition (BOAC.U)
Pine Island Acquisition (PIPP.U)
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Roman DBDR Tech Acquisition (DBDRU)
Ajax I (AJAX.U)
Atlas Crest Investment Corp. (ACICU)
Absolute Software (ABST)
Upcoming IPO
Caliber Home Loans, Inc. (HOMS)
Allegro MicroSystems, Inc. (ALGM)
Mavenir plc (MVNR)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
AmeriHome, Inc. (AHM)
OTR Acquisition (OTRAU)
New Beginnings Acquisition (NBA.U)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Priced IPO
Foghorn Therapeutics Inc. (FHTX)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Datto Holding Corp. (MSP)
MingZhu Logistics Holdings (YGMZ)
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
Array Technologies, Inc. (ARRY)
MINISO Group Holding Limited (MNSO)
Codiak BioSciences, Inc. (CDAK)
Intrusion Securties Inc. (INTZ)
iHuman Inc. (IH)
Shattuck Labs, Inc. (STTK)
Kronos Bio, Inc. (KRON)
Spruce Biosciences, Inc. (SPRB)
Aziyo Biologics, Inc. (AZYO)
More companies

Progenity, Inc. (PROG)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a biotechnology company with an established track record of success in developing and commercializing molecular testing products as well as innovating in the field of precision medicine. They believe that they are a market-leading provider of in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making critical and timely medical decisions during various life stages, such as family planning, pregnancy, or navigating a complex disease diagnosis. Their vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. They apply a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics, to their molecular testing products and to the development of a suite of investigational ingestible devices and drug/device combinations designed to provide precise diagnostic sampling and drug delivery solutions. Their internal core competencies, deep research and development pipeline and strategic acquisitions of novel technologies have fueled their innovation in women’s health, supporting the development and launch of complementary molecular testing products that inform critical healthcare decision-making across a woman’s lifetime.
Harry Stylli Eric d’Esparbes
Employees Founded
674 2011


Address: 4330 La Jolla Village Drive, Suite 200, San Diego, CA 92122, US

Telephone: (855) 293-2639

Web page:

IPO information

Expected Date 6/19/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $677.4
Revenues (MM) $113.3
Net Income (Loss) (MM) $-141.2


What do you think will happen with the PROG share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 6.66
Shares Revised (MM) 6.66
Expected offer amount (MM) $100
Realized offer amount(MM) $99.9
Piper Sandler/ Wells Fargo Securities
Baird/ Raymond James/ BTIG

Sector: Healthcare

Tweets about $PROG

Tweets volume:

RT volume:


Google Trends Stats